I
Description
ImmuPharma PLC is a biopharmaceutical company listed on the London Stock Exchange (IMM.L), specializing in peptide-based therapeutics for autoimmune diseases, inflammation, and anti-infectives. Lead programs: Lupuzor™ for lupus (Phase III), BioAMB (safer amphotericin B), BioCIN (vancomycin-based), and Kapiglucagon for diabetes (IND-enabling stage). Headquartered in London.